Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial

Joana B Neves1, Hannah Warren1, Joseph Santiapillai1

  • 1Division of Surgery and Interventional Sciences, University College London, London, UK; Specialist Centre for Kidney Cancer, Royal Free Hospital, London, UK.

European Urology
|September 8, 2023
PubMed

Insights

This study shows that a trial comparing cryoablation (CRA) to robotic partial nephrectomy (RPN) for small renal masses is feasible. Most patients agreed to participate, supporting future large-scale management trials.

Area of Science:

  • Urology
  • Oncology
  • Clinical Trials

Background:

  • Limited high-level evidence exists for small renal mass (SRM) management.
  • Previous randomized controlled trials (RCTs) for SRMs faced recruitment challenges.

Purpose of the Study:

  • To assess the feasibility of recruiting participants to a cohort-embedded RCT comparing cryoablation (CRA) and robotic partial nephrectomy (RPN).

Main Methods:

  • A cohort of 200 participants was recruited, with 50 enrolled in the embedded RCT.
  • The study compared consent, enrollment, and retention rates for CRA versus RPN.
  • Key outcomes included complication rates, hospital stay, and changes in renal function at 6 months.

Main Results:

  • High consent (84%) and retention (90%) rates were observed in the RCT.
  • Cryoablation (CRA) was associated with fewer postoperative complications (12% vs 29%) and shorter hospital stays (1 vs 2 days) compared to robotic partial nephrectomy (RPN).
  • Renal function changes at 6 months were comparable between CRA (-5.0 ml/min/1.73 m²) and RPN (-5.8 ml/min/1.73 m²).

Conclusions:

  • A cohort-embedded RCT design is feasible for comparing SRM treatments like CRA and RPN.
  • The findings support the feasibility of conducting larger multicenter trials on SRM management strategies.